These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1507200)

  • 21. Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.
    Curtin ML; Davidsen SK; Heyman HR; Garland RB; Sheppard GS; Florjancic AS; Xu L; Carrera GM; Steinman DH; Trautmann JA; Albert DH; Magoc TJ; Tapang P; Rhein DA; Conway RG; Luo G; Denissen JF; Marsh KC; Morgan DW; Summers JB
    J Med Chem; 1998 Jan; 41(1):74-95. PubMed ID: 9438024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological profile of F-0401, a novel dihydropyridine derivative. III. The anti-aggregatory action of F-0401 on rabbit platelets].
    Kase N; Tamura N; Yamaura T; Ohnishi H
    Yakugaku Zasshi; 1995 Jan; 115(1):52-61. PubMed ID: 7699581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding.
    Herbert JM; Laplace MC; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting dihydropyridine calcium antagonists. 5. Synthesis and structure-activity relationships for a series of 2-[[(N-substituted-heterocyclyl)ethoxy]methyl]-1,4-dihydropyridine calcium antagonists.
    Alker D; Campbell SF; Cross PE; Burges RA; Carter AJ; Gardiner DG
    J Med Chem; 1990 Jun; 33(6):1805-11. PubMed ID: 2342074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationships in platelet-activating factor (PAF antagonists). 6. Synthesis and in vitro antagonistic activities of 2-substituted 5-oxotetrahydrofurans.
    Favre E; Heymans F; Redeuilh C; Batt JP; Massicot F; Blavet N; Braquet P; Godfroid JJ
    J Lipid Mediat; 1992 Feb; 5(1):23-40. PubMed ID: 1449553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of [3H]platelet activating factor (PAF) binding by Zn2+: a possible explanation for its specific PAF antiaggregating effects in human platelets.
    Nunez D; Kumar R; Hanahan DJ
    Arch Biochem Biophys; 1989 Aug; 272(2):466-75. PubMed ID: 2502069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Itoh K; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):541-50. PubMed ID: 8004699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on anti-platelet agents. II. Synthesis and platelet-inhibitory activity of 5-methyl-4-(3-pyridyl)-2-(substituted benzimidazol-5-yl)imidazoles.
    Tanaka A; Ito K; Nishino S; Motoyama Y; Takasugi H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):560-9. PubMed ID: 8004701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.
    Herbert JM; Fraisse L; Bachy A; Valette G; Savi P; Laplace MC; Lassalle J; Roche B; Lale A; Keane PE
    J Lipid Mediat; 1993 Aug; 8(1):31-51. PubMed ID: 8257776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet activating factor antagonists: synthesis and structure-activity studies of novel PAF analogues modified in the phosphorylcholine moiety.
    Takatani M; Yoshioka Y; Tasaka A; Terashita Z; Imura Y; Nishikawa K; Tsushima S
    J Med Chem; 1989 Jan; 32(1):56-64. PubMed ID: 2909744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and platelet-activating factor (PAF)-antagonistic activities of trisubstituted piperazine derivatives.
    Fukushi H; Mabuchi H; Terashita Z; Nishikawa K; Sugihara H
    Chem Pharm Bull (Tokyo); 1994 Mar; 42(3):551-9. PubMed ID: 8004700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PAF inhibitory activity of diketopiperazines: structure-activity relationships.
    Shimazaki N; Shima I; Okamoto M; Yoshida K; Hemmi K; Hashimoto M
    Lipids; 1991 Dec; 26(12):1175-8. PubMed ID: 1819704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
    Yue TL; Rabinovici R; Farhat M; Feuerstein G
    J Lipid Mediat; 1991; 3(1):13-26. PubMed ID: 1768837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
    Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
    J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the reversed passive Arthus and local Shwartzman reactions of rabbit skin: effects of the long-acting PAF antagonist UK-74,505.
    Norman KE; Williams TJ; Rossi AG
    Br J Pharmacol; 1997 Apr; 120(7):1286-93. PubMed ID: 9105704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.
    Albert DH; Conway RG; Magoc TJ; Tapang P; Rhein DA; Luo G; Holms JH; Davidsen SK; Summers JB; Carter GW
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1595-606. PubMed ID: 8667228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.
    Meanwell NA; Pearce BC; Roth HR; Smith EC; Wedding DL; Wright JJ; Buchanan JO; Baryla UM; Gamberdella M; Gillespie E
    J Med Chem; 1992 Jul; 35(14):2672-87. PubMed ID: 1321910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen.
    Kuitert LM; Hui KP; Uthayarkumar S; Burke W; Newland AC; Uden S; Barnes NC
    Am Rev Respir Dis; 1993 Jan; 147(1):82-6. PubMed ID: 8420437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
    J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.